Rik H G Olde Engberink1, Nienke M G Rorije1, Hiddo J Lambers Heerspink2, Dick De Zeeuw2, Bert-Jan H van den Born3, Liffert Vogt1. 1. Division of Nephrology, Academic Medical Center, University of Amsterdam, Amsterdam. 2. Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen. 3. Division of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
Abstract
AIMS: Sulodexide is a highly purified mixture of glycosaminoglycans that has been studied for its anti-albuminuric potential. Considering the effects of glycosaminoglycans on endothelial function and sodium homeostasis, we hypothesized that sulodexide may lower blood pressure (BP). In this meta-analysis, we therefore investigated the antihypertensive effects of sulodexide treatment. METHODS: We selected randomized controlled trials that investigated sulodexide treatment of at least 4 weeks and measured BP at baseline and after treatment. Two reviewers independently extracted data on study design, risk of bias, population characteristics and outcome measures. In addition, we contacted authors and pharmaceutical companies to provide missing data. RESULTS: Eight studies, totalling 3019 subjects (mean follow-up 4.4 months) were included. Mean age was 61 years and mean baseline BP was 135/75 mmHg. Compared with control treatment, sulodexide resulted in a significant systolic (2.2 mmHg [95% CI 0.3, 4.1], P = 0.02) and diastolic BP reduction (1.7 mmHg [95% CI 0.6, 2.9], P = 0.004). Hypertensive patients displayed the largest systolic BP and diastolic BP reductions (10.2/5.4 mmHg, P < 0.001). Higher baseline systolic and diastolic BP were significantly associated with larger systolic (r(2)=0.83, P < 0.001) and diastolic BP (r(2)=0.41, P = 0.02) reductions after sulodexide treatment. In addition, systolic (r(2)=0.41, P = 0.03) and diastolic BP reductions (r(2)=0.60, P = 0.005) were significantly associated with albuminuria reduction. CONCLUSION: Our data suggest that sulodexide treatment results in a significant BP reduction, especially in hypertensive subjects. This indicates that endothelial glycosaminoglycans might be an independent therapy target in cardiovascular disease. Future studies should further address the BP lowering potential of sulodexide.
AIMS: Sulodexide is a highly purified mixture of glycosaminoglycans that has been studied for its anti-albuminuric potential. Considering the effects of glycosaminoglycans on endothelial function and sodium homeostasis, we hypothesized that sulodexide may lower blood pressure (BP). In this meta-analysis, we therefore investigated the antihypertensive effects of sulodexide treatment. METHODS: We selected randomized controlled trials that investigated sulodexide treatment of at least 4 weeks and measured BP at baseline and after treatment. Two reviewers independently extracted data on study design, risk of bias, population characteristics and outcome measures. In addition, we contacted authors and pharmaceutical companies to provide missing data. RESULTS: Eight studies, totalling 3019 subjects (mean follow-up 4.4 months) were included. Mean age was 61 years and mean baseline BP was 135/75 mmHg. Compared with control treatment, sulodexide resulted in a significant systolic (2.2 mmHg [95% CI 0.3, 4.1], P = 0.02) and diastolic BP reduction (1.7 mmHg [95% CI 0.6, 2.9], P = 0.004). Hypertensivepatients displayed the largest systolic BP and diastolic BP reductions (10.2/5.4 mmHg, P < 0.001). Higher baseline systolic and diastolic BP were significantly associated with larger systolic (r(2)=0.83, P < 0.001) and diastolic BP (r(2)=0.41, P = 0.02) reductions after sulodexide treatment. In addition, systolic (r(2)=0.41, P = 0.03) and diastolic BP reductions (r(2)=0.60, P = 0.005) were significantly associated with albuminuria reduction. CONCLUSION: Our data suggest that sulodexide treatment results in a significant BP reduction, especially in hypertensive subjects. This indicates that endothelial glycosaminoglycans might be an independent therapy target in cardiovascular disease. Future studies should further address the BP lowering potential of sulodexide.
Authors: Petra Nijst; Frederik H Verbrugge; Lars Grieten; Matthias Dupont; Paul Steels; W H Wilson Tang; Wilfried Mullens Journal: J Am Coll Cardiol Date: 2015-02-03 Impact factor: 24.094
Authors: Edmund J Lewis; Julia B Lewis; Tom Greene; Lawrence G Hunsicker; Tomas Berl; Marc A Pohl; Dick de Zeeuw; Hiddo Lambers Heerspink; Richard D Rohde; Robert C Atkins; Anne T Reutens; David K Packham; Itamar Raz Journal: Am J Kidney Dis Date: 2011-08-26 Impact factor: 8.860
Authors: David K Packham; Rory Wolfe; Anne T Reutens; Tomas Berl; Hiddo Lambers Heerspink; Richard Rohde; Sara Ivory; Julia Lewis; Itamar Raz; Thomas B Wiegmann; Juliana C N Chan; Dick de Zeeuw; Edmund J Lewis; Robert C Atkins Journal: J Am Soc Nephrol Date: 2011-10-27 Impact factor: 10.121
Authors: Jens Titze; Mehdi Shakibaei; Markus Schafflhuber; Gundula Schulze-Tanzil; Markus Porst; Karl H Schwind; Peter Dietsch; Karl F Hilgers Journal: Am J Physiol Heart Circ Physiol Date: 2004-02-19 Impact factor: 4.733
Authors: M Condorelli; M Chiariello; A Dagianti; M Penco; S Dalla Volta; V Pengo; L Schivazappa; G Mattioli; A V Mattioli; B Brusoni Journal: J Am Coll Cardiol Date: 1994-01 Impact factor: 24.094
Authors: Agnes Machnik; Wolfgang Neuhofer; Jonathan Jantsch; Anke Dahlmann; Tuomas Tammela; Katharina Machura; Joon-Keun Park; Franz-Xaver Beck; Dominik N Müller; Wolfgang Derer; Jennifer Goss; Agata Ziomber; Peter Dietsch; Hubertus Wagner; Nico van Rooijen; Armin Kurtz; Karl F Hilgers; Kari Alitalo; Kai-Uwe Eckardt; Friedrich C Luft; Dontscho Kerjaschki; Jens Titze Journal: Nat Med Date: 2009-05-03 Impact factor: 53.440
Authors: Hiddo Lambers Heerspink; Tom Greene; Julia B Lewis; Itamar Raz; Richard D Rohde; Lawrence G Hunsicker; Sherwyn L Schwartz; Stephen Aronoff; Murray A Katz; Gilbert M Eisner; James H Mersey; Thomas B Wiegmann Journal: Nephrol Dial Transplant Date: 2007-12-18 Impact factor: 5.992
Authors: Eliane F E Wenstedt; Jetta J Oppelaar; Stijn Besseling; Nienke M G Rorije; Rik H G Olde Engberink; Arie Oosterhof; Toin H van Kuppevelt; Bert-Jan H van den Born; Jan Aten; Liffert Vogt Journal: J Transl Med Date: 2021-01-20 Impact factor: 5.531